An observational cohort study comparing treatment retention between biosimilars and their originator products among first starters (etanercept, infliximab, adalimumab and rituximab), as well as after non-medical switch
Latest Information Update: 23 Dec 2021
Price :
$35 *
At a glance
- Drugs Adalimumab (Primary) ; Adalimumab (Primary) ; Adalimumab (Primary) ; Adalimumab (Primary) ; Adalimumab (Primary) ; Etanercept (Primary) ; Etanercept (Primary) ; Etanercept (Primary) ; Infliximab (Primary) ; Infliximab (Primary) ; Infliximab (Primary) ; Infliximab (Primary) ; Infliximab (Primary) ; Infliximab (Primary) ; Infliximab (Primary) ; Infliximab (Primary) ; Rituximab (Primary) ; Rituximab (Primary) ; Rituximab (Primary)
- Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis
- Focus Therapeutic Use
- 23 Dec 2021 New trial record
- 17 Dec 2021 Results published in the Rheumatology